Filing Details

Accession Number:
0001140361-13-009782
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-02-28 15:06:14
Reporting Period:
2013-02-27
Filing Date:
2013-02-28
Accepted Time:
2013-02-28 15:06:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1048477 Biomarin Pharmaceutical Inc BMRN Pharmaceutical Preparations (2834) 680397820
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1207604 Alan Lewis C/O Biomarin Pharmaceutical Inc.
105 Digital Drive
Novato CA 94949
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-02-27 7,500 $38.59 23,400 No 4 M Direct
Common Stock Acquisiton 2013-02-27 7,500 $14.39 30,900 No 4 M Direct
Common Stock Acquisiton 2013-02-27 7,500 $21.51 38,400 No 4 M Direct
Common Stock Disposition 2013-02-27 22,500 $56.57 15,900 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Common Stock Disposition 2013-02-27 7,500 $0.00 7,500 $38.59
Common Stock Stock Option (right to buy) Common Stock Disposition 2013-02-27 7,500 $0.00 7,500 $14.39
Common Stock Stock Option (right to buy) Common Stock Disposition 2013-02-27 7,500 $0.00 7,500 $21.51
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
61,000 2018-05-21 No 4 M Direct
53,500 2019-05-11 No 4 M Direct
46,000 2020-05-11 No 4 M Direct
Footnotes
  1. The price in column 4 is weighted average price. The price actually received ranged from $56.39 to $56.86. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  2. This stock option is fully vested and therefore is currently exercisable for 100% of shares.